CAV1 and hepatocellular carcinoma: Collectively, our findings suggest CAV1-driven pathways and autophagy may play pivotal roles in mediating resistance to both sorafenib and lenvatinib, and therefore, selective inhibition of these pathways could potentially hinder HCC progression, overcome TKI resistance, and mitigate the risk of recurrence in HCC patients.